
About Supriya Lifescience
Supriya Lifescience is a publicly listed company based in Mumbai (India) founded in 2008 by Satish Wagh. Active pharmaceutical ingredients and intermediates are manufactured. The company has 555 employees. Its Indian entity Supriya Lifescience Limited reported revenue of βΉ839 Cr. Supriya Lifescience offers products and services including APIs and FDF. Its focus areas include Traditional Pharmaceuticals and Active Pharmaceutical Ingredients.
Company details
Supriya Lifescience was established in 2008 and is based in Mumbai, India. Operations are centered on the production of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates within the healthcare sector. Manufacturing processes are conducted to support pharmaceutical supply chains. The company is led by founder Satish Wagh. Focus remains on quality-controlled production for global markets, with activities aligned to regulatory standards in the industry.
- Headquarters Mumbai, India
- Employees 555
- Founders Satish Wagh
- Stage Public
- SectorsHealthcare
- Website supriyalifescience.com
- Social LinkedIn X
- Legal Name Supriya Lifescience Limited
- Market Cap₹5,030 Cr
SUPRIYA · NSE
- Share Price₹620.15
-0.78% today
- Revenue₹828 Cr
FY 2025-26 · +18.9% YoY
- EBITDA₹294 Cr
Margin 35.6%
- Net Profit₹209 Cr
FY 2025-26 · +11.3% YoY
- P/E (TTM)27.9x
P/B 4.0x
- ROE19.1%
ROCE 25.1%
- Employee Count555
Associated legal entities of Supriya Lifescience
Supriya Lifescience operates through Supriya Lifescience Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Supriya Lifescience Limited Listed CIN L51900MH2008PLC180452 | Active | 26 Mar 2008 | Mumbai, Maharashtra | ₹839 Cr | 450 | 12 | View details |
Products & Services of Supriya Lifescience
Supriya Lifescience offers a comprehensive portfolio of products and services, including APIs and FDF.
Active pharmaceutical ingredients are manufactured and supplied for therapeutic uses in various diseases.
Finished dosage forms are developed and commercialized to address infections and other health conditions.
Board of directors of Supriya Lifescience Limited (Supriya Lifescience)
Supriya Lifescience Limited is the primary company behind Supriya Lifescience. The board of Supriya Lifescience Limited currently have 10 directors; the longest-serving is Smita Satish Wagh, appointed in 2008. 16 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Smita Satish Wagh DIN 00833912 | Whole-time director | 26 Mar 2008 | 18 yrs 7 mo | Supriya Lifescience Limited |
| Satish Waman Wagh DIN 01456982 | Whole-time director | 26 Mar 2008 | 18 yrs 7 mo | Supriya Lifescience Limited |
| Neelam Yashpal Arora DIN 01603068 | Director | 25 Mar 2021 | 5 yrs 7 mo | Supriya Lifescience Limited |
| Saloni Satish Wagh DIN 08491410 | Managing Director | 01 Jul 2022 | 4 yrs 4 mo | Supriya Lifescience Limited |
| Shivani Satish Wagh DIN 08491420 | Managing Director | 01 Jul 2022 | 4 yrs 4 mo | Supriya Lifescience Limited |
| Balasaheb Gulabrao Sawant DIN 07743507 | Whole-time director | 26 May 2023 | 3 yrs 5 mo | Supriya Lifescience Limited |
| Ganapati Dadasaheb Yadav DIN 02235661 | Additional Director | 24 Jan 2025 | 1 yr 9 mo | Supriya Lifescience Limited |
| Sunil Subhash Bhagwat DIN 10178976 | Additional Director | 24 Jan 2025 | 1 yr 9 mo | Supriya Lifescience Limited |
| Manish Ishwarlal Panchal DIN 08431492 | Additional Director | 09 Feb 2026 | 9 mo | Supriya Lifescience Limited |
| Kothandaraman Hari DIN 08901674 | Additional Director | 09 Feb 2026 | 9 mo | Supriya Lifescience Limited |
People of Supriya Lifescience
7 people are tracked at Supriya Lifescience (6 in leadership, 1 in team); the tracked headcount is 555.
| Name | Role | Group |
|---|---|---|
| Founder | Leadership | |
Rajesh Joshi | General Manager | Leadership |
Rajeev Jain | Chief Executive Officer | Leadership |
Sreekant Sreedharan | General Manager | Leadership |
Krishna Raghunathan | Chief Financial Officer | Leadership |
Shekhar Bhirud | Director Business Development And Strategy | Leadership |
Renuka Kapare | Marketing & BD Executive - Europe | Team |
Complete people profiles for Supriya Lifescience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Supriya Lifescience
Supriya Lifescience is a publicly listed company on the NSE with ticker symbol SUPRIYA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Dec 2021
- Listed onBSE: 543434 · NSE: SUPRIYA
- Listed entitySupriya Lifescience Limited
- Exchange sectorHealth technology
- ISININE07RO01027
- Share price₹875.60 (-0.75% on the day) · 2026-10-14
- Market capitalisation₹7,106 Cr
- Price to earnings35.5
- EPS (diluted, trailing year)₹24.65
- Dividend yield0.12%
- Volume (last session)97,563
Financials of Supriya Lifescience
Exchange-reported figures of Supriya Lifescience Limited, the listed company behind Supriya Lifescience (NSE: SUPRIYA).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 828 | 696 | 570 | 461 | 530 | 391 | 312 |
| Revenue growth | +18.9% | +22.1% | +23.7% | -13.0% | +35.5% | +25.5% | - |
| EBITDA | 294 | 261 | 176 | 129 | 214 | 173 | 98.38 |
| EBITDA margin | +35.6% | +37.5% | +30.9% | +28.0% | +40.4% | +44.3% | +31.6% |
| Profit before tax | 275 | 248 | 166 | 123 | 207 | 167 | 96.19 |
| Net profit | 209 | 188 | 119 | 89.94 | 152 | 124 | 73.35 |
| Net profit margin | +25.3% | +27.0% | +20.9% | +19.5% | +28.6% | +31.6% | +23.5% |
| EPS (βΉ) | 25.98 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 | 50.11 |
| Balance sheet | |||||||
| Total assets | 1,205 | 1,003 | 822 | 728 | 646 | 362 | 253 |
| Net worth | 1,198 | 997 | 815 | 699 | 616 | 269 | 149 |
| Total debt | 5.44 | 5.38 | 5.49 | 22.47 | 27.42 | 72.19 | 82.21 |
| Cash & bank | 78.87 | 79.15 | 74.96 | 158 | 228 | 89.28 | 74.71 |
| Net working capital | 412 | 355 | 321 | 386 | 420 | 190 | 120 |
| Cash flow | |||||||
| Cash from operations | 186 | 165 | 113 | 63.61 | 48.80 | 75.89 | 117 |
| Cash from investing | (176) | (152) | (174) | (124) | (59.82) | (46.80) | (25.14) |
| Cash from financing | (9.88) | (8.23) | (22.36) | (10.28) | 150 | (14.52) | (29.23) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 206 | 190 | 277 | 206 | 200 | 145 | 184 | 186 |
| Revenue growth (YoY) | +3.2% | +30.8% | +50.2% | +11.2% | +20.3% | -9.7% | - | - |
| Other income | 2.29 | 2.65 | 3.48 | 2.61 | 2.73 | 2.67 | 2.98 | 2.10 |
| Total expenses | 161 | 142 | 179 | 135 | 127 | 93.37 | 117 | 120 |
| EBITDA | 45.40 | 47.46 | 97.62 | 71.62 | 72.64 | 51.70 | 67.58 | 65.95 |
| EBITDA margin | +22.0% | +25.0% | +35.3% | +34.7% | +36.4% | +35.6% | +36.7% | +35.5% |
| Depreciation | 9.46 | 8.94 | 8.50 | 6.82 | 6.64 | 6.45 | 6.08 | 4.96 |
| Interest | 0.46 | 0.37 | 0.47 | 0.49 | 0.42 | 0.51 | 0.42 | 0.51 |
| Profit before tax | 37.77 | 40.80 | 92.13 | 66.92 | 68.31 | 47.41 | 64.06 | 62.58 |
| Tax | 8.53 | 16.75 | 17.90 | 17.24 | 17.89 | 12.63 | 13.68 | 15.80 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 206 | 190 | 277 | 206 | 200 | 145 | 184 | 186 |
| Revenue growth (YoY) | +3.2% | +30.8% | +50.2% | +11.2% | +20.3% | -9.7% | - | - |
| Other income | 2.29 | 2.65 | 3.48 | 2.61 | 2.73 | 2.67 | 2.98 | 2.10 |
| Total expenses | 161 | 142 | 179 | 135 | 127 | 93.37 | 117 | 120 |
| EBITDA | 45.40 | 47.46 | 97.62 | 71.62 | 72.64 | 51.70 | 67.58 | 65.95 |
| EBITDA margin | +22.0% | +25.0% | +35.3% | +34.7% | +36.4% | +35.6% | +36.7% | +35.5% |
| Depreciation | 9.46 | 8.94 | 8.50 | 6.82 | 6.64 | 6.45 | 6.08 | 4.96 |
| Interest | 0.46 | 0.37 | 0.47 | 0.49 | 0.42 | 0.51 | 0.42 | 0.51 |
| Profit before tax | 37.77 | 40.80 | 92.13 | 66.92 | 68.31 | 47.41 | 64.06 | 62.58 |
| Tax | 8.53 | 16.75 | 17.90 | 17.24 | 17.89 | 12.63 | 13.68 | 15.80 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 828 | 696 | 570 | 461 | 530 | 391 | 312 |
| Revenue growth | +18.9% | +22.1% | +23.7% | -13.0% | +35.5% | +25.5% | - |
| Other income | 11.49 | 9.82 | 10.64 | 9.49 | 7.58 | 5.01 | 11.07 |
| Total expenses | 533 | 436 | 394 | 332 | 316 | 218 | 213 |
| Employee cost | 96.68 | 80.52 | 67.64 | 55.58 | 49.08 | 32.76 | 18.88 |
| EBITDA | 294 | 261 | 176 | 129 | 214 | 173 | 98.38 |
| EBITDA margin | +35.6% | +37.5% | +30.9% | +28.0% | +40.4% | +44.3% | +31.6% |
| Depreciation | 28.41 | 20.44 | 15.81 | 11.82 | 10.12 | 6.76 | 6.41 |
| Interest | 2.77 | 1.81 | 5.15 | 3.08 | 4.20 | 4.08 | 6.85 |
| Profit before tax | 275 | 248 | 166 | 123 | 207 | 167 | 96.19 |
| Tax | 65.66 | 60.53 | 46.58 | 33.63 | 55.44 | 43.71 | 22.84 |
| Net profit | 209 | 188 | 119 | 89.94 | 152 | 124 | 73.35 |
| Net profit margin | +25.3% | +27.0% | +20.9% | +19.5% | +28.6% | +31.6% | +23.5% |
| EPS (βΉ) | 25.98 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 | 50.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 16.10 | 16.10 | 16.10 | 16.10 | 16.10 | 14.64 | 14.64 |
| Reserves & surplus | 1,182 | 981 | 799 | 683 | 600 | 254 | 134 |
| Shareholders' funds (net worth) | 1,198 | 997 | 815 | 699 | 616 | 269 | 149 |
| Secured loans | 0.00 | 0.00 | 0.00 | 16.63 | 21.30 | 66.38 | 78.12 |
| Unsecured loans | 5.44 | 5.38 | 5.49 | 5.84 | 6.12 | 5.81 | 4.09 |
| Total debt | 5.44 | 5.38 | 5.49 | 22.47 | 27.42 | 72.19 | 82.21 |
| Total liabilities | - | - | 822 | 728 | 646 | 362 | 253 |
| Assets | |||||||
| Gross block | 799 | 534 | 371 | 306 | 223 | 123 | 115 |
| Net block | 689 | 453 | 310 | 262 | 190 | 100 | 98.58 |
| Capital work in progress | 35.55 | 148 | 149 | 67.63 | 43.41 | 78.79 | 40.21 |
| Investments | 98.52 | 63.24 | 63.80 | 25.30 | 0.05 | 0.05 | 0.05 |
| Inventories | 160 | 118 | 85.25 | 116 | 92.31 | 72.48 | 49.46 |
| Sundry debtors | 219 | 134 | 112 | 84.66 | 115 | 73.50 | 51.63 |
| Cash & bank balances | 78.87 | 79.15 | 74.96 | 158 | 228 | 89.28 | 74.71 |
| Loans & advances | 74.39 | 110 | 126 | 107 | 62.14 | 30.21 | 19.81 |
| Total current assets | 532 | 442 | 398 | 465 | 498 | 265 | 196 |
| Total current liabilities | 121 | 86.87 | 76.64 | 78.80 | 77.58 | 75.90 | 75.57 |
| Net working capital | 412 | 355 | 321 | 386 | 420 | 190 | 120 |
| Total assets | 1,205 | 1,003 | 822 | 728 | 646 | 362 | 253 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 79.15 | 74.96 | 158 | 228 | 89.28 | 74.71 | 12.40 |
| Net cash from operating activities | 186 | 165 | 113 | 63.61 | 48.80 | 75.89 | 117 |
| Net cash from investing activities | (176) | (152) | (174) | (124) | (59.82) | (46.80) | (25.14) |
| Net cash from financing activities | (9.88) | (8.23) | (22.36) | (10.28) | 150 | (14.52) | (29.23) |
| Net change in cash | (0.29) | 4.20 | (82.63) | (70.33) | 139 | 14.57 | 62.31 |
| Closing cash | 78.87 | 79.15 | 74.96 | 158 | 228 | 89.28 | 74.71 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +18.9% | +22.1% | +23.7% | -13.0% | +35.5% | +25.5% | - |
| EBITDA growth | +12.9% | +48.2% | +36.6% | -39.8% | +23.6% | +76.0% | - |
| PBT growth | +10.6% | +50.0% | +34.2% | -40.4% | +23.9% | +73.9% | -22.0% |
| Net income growth | +11.3% | +57.8% | +32.4% | -40.8% | +22.8% | +68.5% | - |
| Revenue CAGR (3Y) | +21.6% | +9.5% | +13.4% | +13.9% | +24.0% | +22.5% | +19.3% |
| EBITDA CAGR (3Y) | +31.7% | +6.8% | +0.6% | +9.4% | +17.8% | +99.1% | +78.2% |
| Profitability & leverage | |||||||
| Net income margin | +25.3% | +27.0% | +20.9% | +19.5% | +28.6% | +31.6% | +23.5% |
| Return on capital employed | +25.1% | +27.4% | +22.1% | +18.4% | +42.0% | +55.8% | +46.5% |
| Return on net worth | +19.1% | +20.7% | +15.7% | +13.7% | +34.3% | +59.2% | +60.4% |
| Debt / equity | 0.00 | 0.01 | 0.02 | 0.04 | 0.11 | 0.37 | 0.71 |
| Long-term debt / equity | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 |
| Interest cover | 1.04 | 0.75 | 3.21 | 2.63 | 2.06 | 2.45 | 7.45 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.37 | 1.73 | 1.91 | 1.95 | 3.40 | 3.62 | 2.98 |
| Inventory turnover | 6.58 | 7.68 | 6.44 | 4.96 | 7.14 | 7.07 | 7.77 |
| Debtors turnover | 5.17 | 6.36 | 6.59 | 5.17 | 6.24 | 6.89 | 5.59 |
| EPS (βΉ) | 25.98 | 23.35 | 14.80 | 11.16 | 18.86 | 16.89 | 50.11 |
| Dividend per share (βΉ) | 1.00 | 1.00 | 0.80 | 0.60 | 0.60 | 0.54 | 10.00 |
| Book value per share (βΉ) | 148.81 | 123.84 | 101.31 | 86.91 | 76.50 | 36.70 | 101.84 |
Web traffic of Supriya Lifescience
The website of Supriya Lifescience (supriyalifescience.com) receives about 5.1K visits a month.
- Monthly visits5.1K
▲ 6.9% vs previous month
Websites whose visitors overlap most with Supriya Lifescience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
screener.in | screener.in | 100% | #1,968 | β | |
| nsdl.co.in | 57% | 1M | #56,731 | View details |
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Supriya Lifescience (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Supriya Lifescience
Complete news archive for Supriya Lifescience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Supriya Lifescience
Supriya Lifescience was founded in 2008.
Supriya Lifescience is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Supriya Lifescience has 555 employees.
The primary company behind Supriya Lifescience, Supriya Lifescience Limited, reported revenue of βΉ839 Cr for FY 2026, up 19% year on year.
Supriya Lifescience was established in 2008 and is based in Mumbai, India. Operations are centered on the production of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates within the healthcare sector. Manufacturing processes are conducted to support pharmaceutical supply chains. The company is led by founder Satish Wagh. Focus remains on quality-controlled production for global markets, with activities aligned to regulatory standards in the industry.
Supriya Lifescience offers APIs and FDF.
Yes, Supriya Lifescience is publicly traded on NSE under the ticker symbol SUPRIYA.
Supriya Lifescience operates through Supriya Lifescience Limited.
The legal entities of Supriya Lifescience currently have 12 directors, including Smita Satish Wagh, Neelam Yashpal Arora, Balasaheb Gulabrao Sawant and others.
